EE311 Evaluating the Cost-Effectiveness of Ruxolitinib for the Treatment of Polycythaemia Vera Patients That Are Resistant/Intolerant to Hydroxycarbamide/Hydroxyurea in England and Wales
Dec 1, 2024, 00:00
10.1016/j.jval.2024.10.593
https://www.valueinhealthjournal.com/article/S1098-3015(24)03456-9/fulltext
Title :
EE311 Evaluating the Cost-Effectiveness of Ruxolitinib for the Treatment of Polycythaemia Vera Patients That Are Resistant/Intolerant to Hydroxycarbamide/Hydroxyurea in England and Wales
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)03456-9&doi=10.1016/j.jval.2024.10.593
First page :
Section Title :
Open access? :
No
Section Order :
10089